Printer Friendly

GEN-PROBE AND MOLECULAR BIOSYSTEMS SETTLE PATENT LITIGATION

 GEN-PROBE AND MOLECULAR BIOSYSTEMS SETTLE PATENT LITIGATION
 SAN DIEGO, Aug. 28 /PRNewswire/ -- Gen-Probe Inc. and Molecular Biosystems Inc. (NYSE: MB) (MBI) announced today they have settled their patent litigation concerning diagnostic test kits using genetic probe technology.
 MBI's wholly owned subsidiary Syngene Inc. agreed that Gen-Probe's U.S. Patent No. 4,851,330 for targeting ribosomal RNA is valid; agreed to be enjoined from manufacturing, using and selling infringing products including its current SNAP(R) mycobacterium diagnostic kits; and agreed to pay Gen-Probe an undisclosed sum. Syngene's counterclaim that Gen-Probe's products infringed Syngene's U.S. Patent No. 4,948,882 was dismissed.
 Thomas A. Bologna, chairman, president and chief executive officer of Gen-Probe, and Vincent A. Frank, president and chief operating officer of Molecular Biosystems, said, "We are very pleased to end this dispute between two of San Diego's leading biotechnology companies."
 Gen-Probe Inc. is a leader in the development and commercialization of medical products based on genetic probe technology, and is ranked as one of the largest biotechnology companies in San Diego.
 Molecular Biosystems Inc. is a leader in the development and manufacturing of contrast agents for medical imaging, including ultrasound and magnetic resonance imaging. MBI's common stock is listed on the New York Stock Exchange under the symbol "MB."
 -0- 8/28/92
 /CONTACT: Thomas A. Bologna, chairman, president and CEO of Gen-Probe, 619-546-8000; or Vincent A. Frank, president and COO of Molecular Biosystems, 619-452-0681/
 (MB) CO: Molecular Biosystems Inc.; Gen-Probe Inc.; Syngene Inc. ST: California IN: MTC SU:


BP-JL -- SD006 -- 4688 08/28/92 19:02 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 28, 1992
Words:260
Previous Article:VITAL HEART SYSTEMS REPORTS COMMUNICATION FROM FDA
Next Article:SAN FRANCISCO SHIP YARD OWNERS INDICTED FOR CLEAN WATER ACT VIOLATIONS
Topics:


Related Articles
GEN-PROBE FILES SUIT AGAINST MOLECULAR BIOSYSTEMS INC. FOR PATENT INFRINGEMENT
MOLECULAR BIOSYSTEMS INC. AND SYNGENE INC. COMMENT ON GEN-PROBE PATENT SUIT
MICROPROBE AGREES GEN-PROBE PATENTS VALID
Judgment Entered in Favor of Gen-Probe in Second Lawsuit Over Key Patents
Gen-Probe Receives Broad U.S. Patent Covering Automated Process for Nucleic Acid Testing.
Gen-Probe Broadens Intellectual Property Portfolio Surrounding Automated Nucleic Acid Testing.
Court Dismisses Gen-Probe Court Action Against Digene.
Court dismisses Gen-Probe court action against Digene.
Gen-Probe Broadens Intellectual Property Portfolio Surrounding Automated Nucleic Acid Testing.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters